AURORA 2 Voclosporin, a novel calcineurin inhibitor (CNI), is associated with a favorable metabolic profile with regard to lipids and glucose, and a predictable pharmacokinetic profile, resulting in no need for the therapeutic drug monitoring required of other CNIs. AURORA 2, a double-blind, phase 3 study, evaluated the longterm safety, tolerability and efficacy of voclosporin…
In this study, Fava et al. investigated longitudinal autoantibody profiles in a racially diverse cohort of patients with lupus nephritis to define noninvasive serological biomarkers of histologic class and one-year treatment response to standard of care. In addition, the researchers determined how these biomarkers changed over time to provide further insights into treatment response and…
“B cells are central orchestraters of autoimmune disease by contributing to autoantibody production, antigen presentation and cytokine production,” says Georg Schett, MD, head of the Department of Medicine 3 (Rheumatology and Immunology) of the Friedrich-Alexander University Erlangen-Nürnberg, Germany. “B cells can be inhibited by monoclonal antibodies and chimeric antigen receptor (CAR) expressing cells.” Dr. Schett…
Renal arteriosclerosis is common in patients with lupus nephritis and occurs two decades earlier than it does in people without the condition, say investigators in a study that examined the prevalence of renal arteriosclerosis in patients with lupus nephritis compared with healthy controls.1 The finding suggests that renal arteriosclerosis could be used as a biomarker…
Experts identify barriers to shared decision making in rheumatology & offer actionable tools to integrate SDM into practice for better patient outcomes.
Discover the latest ILD management strategies for RA, SSc & myositis, plus expert guidance on pregnancy & defining progressive pulmonary fibrosis.
Research on PT for knee OA, HCQ’s protective role in lupus nephritis & the link between RA disease activity & frailty.
In a recent Arthritis & Rheumatology review article, three experts discuss the use of immunosuppressants to target B cells in a patient with systemic sclerosis-interstitial lung disease.
New EULAR/ACR criteria help stratify RA risk in patients with arthralgia. Learn how these criteria guide earlier interventions & improve trial rigor.
The gut microbiome may trigger RA & predict methotrexate response. ACR Convergence 2025 experts discuss pathogenesis & drug efficacy.